However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

For Q1 2025, GoPro expects revenue of $125M, plus or minus $10M, a 20% decline year-over-year. Gross margin is anticipated at 35%, with operating expenses of approximately $63M, reflecting a 24% ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

Q4 2024 Earnings Call Transcript February 4, 2025 FMC Corporation beats earnings expectations. Reported EPS is $1.79, ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...